Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Non-Current Deffered Revenue (2016 - 2018)

Altimmune (ALT) has disclosed Non-Current Deffered Revenue for 5 consecutive years, with $1.0 million as the latest value for Q4 2018.

  • Quarterly Non-Current Deffered Revenue rose 170.59% to $1.0 million in Q4 2018 from the year-ago period, while the trailing twelve-month figure was $1.0 million through Dec 2018, up 170.59% year-over-year, with the annual reading at $1.0 million for FY2018, 170.59% up from the prior year.
  • Non-Current Deffered Revenue for Q4 2018 was $1.0 million at Altimmune, down from $1.1 million in the prior quarter.
  • The five-year high for Non-Current Deffered Revenue was $1.1 million in Q2 2018, with the low at $6366.0 in Q2 2017.
  • Average Non-Current Deffered Revenue over 3 years is $640662.4, with a median of $716148.0 recorded in 2017.
  • The sharpest move saw Non-Current Deffered Revenue surged 115.41% in 2017, then skyrocketed 17722.45% in 2018.
  • Over 3 years, Non-Current Deffered Revenue stood at $179424.0 in 2016, then soared by 115.41% to $386489.0 in 2017, then skyrocketed by 170.59% to $1.0 million in 2018.
  • According to Business Quant data, Non-Current Deffered Revenue over the past three periods came in at $1.0 million, $1.1 million, and $1.1 million for Q4 2018, Q3 2018, and Q2 2018 respectively.